SCHEMBL7157263

SCHEMBL7157263

CCOC(=O)/C(=C/Nc1cccc([N+](=O)[O-])c1)C(=O)c1cccnc1Cl

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.52
GLO1 Q04760 1/20 0.47
DHODH Q02127 2/20 0.47
NPSR1 Q6W5P4 4/20 0.46
MEN1 O00255 2/20 0.46
NPC1 O15118 2/20 0.46
HSP90AA1 P07900 1/20 0.46
PKM P14618 1/20 0.46
HPGD P15428 1/20 0.46
CCR6 P51684 1/20 0.46
APOBEC3G Q9HC16 1/20 0.46
MAPT P10636 8/20 0.45
CYP1A2 P05177 2/20 0.45
CYP2C19 P33261 2/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2D6 P10635 1/20 0.45
MAPK1 P28482 1/20 0.45
ALDH1A1 P00352 2/20 0.45
RAB9A P51151 1/20 0.45
KCNH2 Q12809 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7157266 1.00 KMT2A (0.52) KMT2AGLO1DHODHNPSR1MEN1
SCHEMBL8246814 0.86 GAA (0.54) KMT2ADHODHNPSR1MEN1HPGD
SCHEMBL8246811 0.85 DHODH (0.50) KMT2ADHODHNPSR1MEN1HPGD
SCHEMBL4947596 0.85 DHODH (0.50) KMT2ADHODHNPSR1MEN1HPGD
SCHEMBL1566802 0.85 DHODH (0.50) KMT2ADHODHNPSR1MEN1HPGD
SCHEMBL4742571 0.84 DHODH (0.64) KMT2AGLO1DHODHNPSR1MEN1
SCHEMBL7157293 0.81 MAPT (0.57) KMT2ADHODHNPSR1MEN1NPC1
SCHEMBL7157291 0.81 MAPT (0.57) KMT2ADHODHNPSR1MEN1NPC1
SCHEMBL7158653 0.81 MAPT (0.53) KMT2ADHODHNPSR1MEN1NPC1
SCHEMBL7158657 0.81 MAPT (0.53) KMT2ADHODHNPSR1MEN1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6541480-B2 Controlling cytokines SUNTORY LIMITED (JP) 2003-04-01 US disclosed
US-20020006935-A1 1-aryl-1,8-naphthylidin-4-one derivative as type IV phosphodiesterase inhibitor DAIICHI ASUBIO PHARMA CO., LTD. (JP) 2002-01-17 US disclosed
US-6297248-B1 1-aryl-1,8-naphthylidin-4-one derivative as type IV phosphodiesterase inhibitor SUNTORY LIMITED (JP) 2001-10-02 US disclosed
EP-0958297-A1 1-ARYL-1,8-NAPHTHYLIDIN-4-ONE DERIVATIVE AS TYPE IV PHOSPHODIESTERASE INHIBITOR SUNTORY LIMITED (JP) 1999-11-24 EP disclosed
WO-1999007704-A1 1-ARYL-1,8-NAPHTHYLIDIN-4-ONE DERIVATIVE AS TYPE IV PHOSPHODIESTERASE INHIBITOR SUNTORY LIMITED (JP) 1999-02-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020006935-A1 1-aryl-1,8-naphthylidin-4-one derivative as type IV phosphodiesterase inhibitor PDE3A, PDE5A, PDE3B KMT2A 2334/4885GLO1 3533/4885DHODH 1321/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.